SG Americas Securities
CRVS icon

SG Americas Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

SG Americas Securities’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$518K Buy
35,420
+15,399
+77% +$246K ﹤0.01% 2164
2025
Q4 		$154K Buy
+20,021
New +$158K ﹤0.01% 3034
2018
Q1 		– Sell
-14,438
Closed -$150K – 3287
2017
Q4 		$150K Buy
+14,438
New +$185K ﹤0.01% 2631

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SG Americas Securities's CRVS Position: Q1 2026 in Review

SG Americas Securities increased its Corvus Pharmaceuticals (CRVS) stake by 77% in Q1 2026, buying an estimated $246K and bringing the position to 35,420 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

SG Americas Securities first reported a position in CRVS in Q4 2017 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • SG Americas Securities held 35,420 shares of Corvus Pharmaceuticals worth $518K as of Q1 2026.
  • SG Americas Securities bought 15,399 Corvus Pharmaceuticals shares in Q1 2026, an estimated $246K.
  • Corvus Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2164 holding.
  • SG Americas Securities first reported a position in Corvus Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.